Market Place
Sourcing Support
MannKind`s Ph 1 Trial of Nintedanib DPI for Pulmonary Fibrosis
04 Nov 2024 //
GLOBENEWSWIRE
Boehringer`s Lung Fibrosis Trial Meets Primary Endpoint
17 Sep 2024 //
FIERCE BIOTECH
MannKind to Proceed with Ph1 Nintedanib DPI (MNKD-201) in PF
30 Apr 2024 //
GLOBENEWSWIRE
U.S. FDA accepts supplemental New Drug Application for OFEV for children
25 Jul 2023 //
PR NEWSWIRE
Lotus` Generic Nintedanib Esylate Receives Approval in the U.S.
12 Jan 2023 //
FDA
Lotus` Generic Nintedanib Receives Approval in the U.S.
12 Jan 2023 //
FDA
New data from Boehringer support the potential use of nintedanib
05 Sep 2022 //
BUSINESSWIRE
NICE approves Ofev for PF-ILD
18 Oct 2021 //
PHARMATIMES
Blade shows +ve Data from Drug-Drug Interaction Study of Cudetaxesta in IPF
20 Sep 2021 //
BUSINESSWIRE
SMC approves nintedanib for patients with chronic lung disease
10 Jun 2021 //
PHARMAFILE
Study analysis available during ATS 2021 supports long-term treatment with Ofev®
14 May 2021 //
PRNEWSWIRE
OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS
04 Mar 2021 //
NEWSWIRE
Boehringer and Icahn School begin enrolment in Covid-19 trial
24 Nov 2020 //
CLINICALTRIALSARENA
CohBar Antifibrotic Peptide in Combination Nintedanib Shows Enhanced Effects
26 Oct 2020 //
PRESS RELEASE
Cipla launches Nintib Idiopathic Pulmonary Fibrosis, in continuation
20 Oct 2020 //
PRESS RELEASE
Boehringer starts enrolment for paediatric trial of nintedanib
12 Aug 2020 //
CLINICALTRIALSARENA
Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib pediatric
11 Aug 2020 //
PRNEWSWIRE
Accord Healthcare`s Generic Nintedanib Receives Approval in US
07 Aug 2020 //
FDA
New Analyses of Ofev® data in patients with chronic fibrosing ILDs during ATSC
05 Aug 2020 //
PRNEWSWIRE
Boehringer Ingelheim gets European approval for additional for nintedanib
16 Jul 2020 //
PHARMABIZ
European Commission approves third nintedanib indication in pulmonary fibrosis1
15 Jul 2020 //
BUSINESSLWIRE
European Commission approves third nintedanib indication in pulmonary fibrosis1
15 Jul 2020 //
BUSINESSLWIRE
BI receives positive CHMP opinion for a third nintedanib indication
29 May 2020 //
BUSINESSWIRE
OFEV® (nintedanib) now available in Canada for adults living with (PF-ILD)(1)
25 May 2020 //
NEWSWIRE
AI VIVO seeks pharma, biotech collaboration partners to advance drug candidates
10 May 2020 //
MEDICAL
CHMP Recommends One New Drug, Begins Review of Indian CRO
29 Feb 2020 //
RAPS
Boehringer’s nintedanib secures breakthrough status in US for ILDs
12 Oct 2019 //
PHARMACEUTICAL TECHNOLOGY
FDA Grants Ofev® Breakthrough Therapy Designation
11 Oct 2019 //
PR NEWSWIRE
Boehringer Ingelheim`s Ofev wins FDA approval for use in scleroderma patients
10 Sep 2019 //
ENDPOINTSNEWS
FDA approves Boehringer`s lung disease drug
06 Sep 2019 //
REUTERS
Ofev set for new US approval, in scleroderma
25 Jul 2019 //
THE PHARMALETTER
Boehringer expands IPF pipeline with addition of BBT-877
19 Jul 2019 //
PHARMATIMES
Nintedanib hits targets in rare lung disease trial
22 May 2019 //
PHARMA TIMES
Phase III study showed nintedanib slows the loss of pulmonary function
21 May 2019 //
BUSUNESSWIRE
Boehringer eyes rare disease use for respiratory blockbuster
21 May 2019 //
PMLIVE
Tium Bio Licenses out Lung Disease Drug Candidate for US$74 Mil
11 Jan 2019 //
KOREA BUSINESS
List of Paragraph IV Patent Certifications as of Dec 18, 2018
22 Dec 2018 //
FDA
Vargatef® plus docetaxel could be option after failure of immunotherapy in LC
13 Dec 2018 //
BUSINESSWIRE
Ofev® (nintedanib) slows progression of IPF beyond 4yrs with consistent safety
17 Sep 2018 //
PR NEWSWIRE
Boehringer sales rise as Jardiance and Ofev thrive
01 Aug 2018 //
PHARMA TIMES
Efficacy and safety of Ofev® reinforced in new presentations at ATS 2018
21 May 2018 //
PR NEWSWIRE
FDA grants Fast Track designation to nintedanib for the of systemic sclerosis
19 Mar 2018 //
BIOSPACE
PIM status for Boehringer’s mesothelioma drug
04 Jan 2018 //
PHARMA TIMES
FibroGen Announces Positive Topline Results from Ph2 Study of Pamrevlumab
15 Aug 2017 //
GLOBENEWSWIRE
IPF patients treated with Ofev v. placebo were twice have improved lung function
24 May 2017 //
PR NEWSWIRE
UK competition watchdog accuses Merck of obstructing biosimilars
23 May 2017 //
REUTERS
Nintedanib granted orphan drug designation for treatment of mesothelioma
14 Dec 2016 //
PR NEWSWIRE
Bristol-Myers pens $100M NASH, fibrosis drug deal with Japan’s Nitto
10 Nov 2016 //
FIERCE BIOTECH
BI unveils new data backing IPF drug Ofev
26 Oct 2016 //
PHARMATIMES
Boehringer`s Vargatef Comes up One Endpoint Short in Colorectal Cancer Effort
13 Oct 2016 //
FIERCE PHARMA
Phase III nintedanib announced at ESMO
11 Oct 2016 //
PR NEWSWIRE
US/EU orphan status for BI’s Ofev in systemic sclerosis
13 Sep 2016 //
PHARMATIMES
New presentations at ATS 2016 reinforce OFEV efficacy, safety and tolerability
17 May 2016 //
CPHI-ONLINE
Boehringer, AbbVie Said to Be in Cancer-Partnership Talks
01 Mar 2016 //
BLOOMBERG
BI launches unique drug for rare disease and revolutionizes panorama treatment
29 Feb 2016 //
PR NEWSWIRE
New analysis OFEV slows disease progression in IPF, reduces risk exacerbations
25 Feb 2016 //
PR NEWSWIRE
New PhIII Study of Nintedanib in People with Systemic Sclerosis,Lung Fibrosis
08 Dec 2015 //
PR NEWS WIRE
New Analyses Further Add to the Efficacy and Safety Profile of OFEV in IPF
13 Nov 2015 //
FINANCIAL EXPRESS
